HUP0002979A2 - Terápiásan több célú, ösztrogén agonista és antagonista vegyületek alkalmazása - Google Patents

Terápiásan több célú, ösztrogén agonista és antagonista vegyületek alkalmazása

Info

Publication number
HUP0002979A2
HUP0002979A2 HU0002979A HUP0002979A HUP0002979A2 HU P0002979 A2 HUP0002979 A2 HU P0002979A2 HU 0002979 A HU0002979 A HU 0002979A HU P0002979 A HUP0002979 A HU P0002979A HU P0002979 A2 HUP0002979 A2 HU P0002979A2
Authority
HU
Hungary
Prior art keywords
antagonists
estrogen agonists
multiple indications
indications
lasofoxifene
Prior art date
Application number
HU0002979A
Other languages
English (en)
Inventor
Julia Yu Li
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of HU0002979D0 publication Critical patent/HU0002979D0/hu
Publication of HUP0002979A2 publication Critical patent/HUP0002979A2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A tal lm ny t rgya a lazofoxifen és a droloxifen alkalmaz sacsontritkul s, szív- és keringési betegségek és mellr k gyógyító ésmegelőző kezelésére, warfarin és propranolol egyidejű alkalmaz samellett. Ó
HU0002979A 1999-07-28 2000-07-27 Terápiásan több célú, ösztrogén agonista és antagonista vegyületek alkalmazása HUP0002979A2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14607299P 1999-07-28 1999-07-28
US14607599P 1999-07-28 1999-07-28

Publications (2)

Publication Number Publication Date
HU0002979D0 HU0002979D0 (en) 2000-10-28
HUP0002979A2 true HUP0002979A2 (hu) 2002-04-29

Family

ID=26843545

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0002979A HUP0002979A2 (hu) 1999-07-28 2000-07-27 Terápiásan több célú, ösztrogén agonista és antagonista vegyületek alkalmazása

Country Status (9)

Country Link
EP (1) EP1086692A3 (hu)
JP (1) JP2001048805A (hu)
KR (1) KR20010049909A (hu)
AU (1) AU4882700A (hu)
CA (1) CA2314572A1 (hu)
HU (1) HUP0002979A2 (hu)
IL (1) IL137428A0 (hu)
NZ (1) NZ506014A (hu)
PE (1) PE20010347A1 (hu)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6436977B1 (en) * 1999-09-29 2002-08-20 Pfizer Inc. Dosing regimens for lasofoxifene
GB2475907A (en) * 2009-12-04 2011-06-08 Tcp Innovations Ltd Composition comprising a mixture of clopidogrel and droloxifene
SG11201903236SA (en) 2016-10-11 2019-05-30 Univ Duke Lasofoxifene treatment of er+ breast cancer
WO2018071437A1 (en) * 2016-10-11 2018-04-19 Sermonix Pharmaceuticals, Llc Lasofoxifene treatment of vva and osteoporosis in survivors of breast cancer and other malignancies
US11497730B2 (en) 2018-04-10 2022-11-15 Duke University Lasofoxifene treatment of breast cancer
GB202116903D0 (en) 2021-11-18 2022-01-05 Sermonix Pharmaceuticals Inc Lasofoxifene treatment of aromatase-resistant er+ cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis

Also Published As

Publication number Publication date
EP1086692A2 (en) 2001-03-28
EP1086692A3 (en) 2003-07-09
JP2001048805A (ja) 2001-02-20
HU0002979D0 (en) 2000-10-28
CA2314572A1 (en) 2001-01-28
PE20010347A1 (es) 2001-03-23
AU4882700A (en) 2001-02-01
KR20010049909A (ko) 2001-06-15
NZ506014A (en) 2001-11-30
IL137428A0 (en) 2001-07-24

Similar Documents

Publication Publication Date Title
Kemeny et al. Superior survival of young women with malignant melanoma
MX9605940A (es) Compuestos bioaromaticos que llevan un grupo adamantilo en orto, composiciones farmaceuticas y cosmeticas que los contienen y utilizaciones.
ATE234274T1 (de) Derivate des adamantan
TR200100054T2 (tr) Paroksetin metansülfonat
PL323364A1 (en) Bicyclic aromatic compounds
IT1216916B (it) Composti aromatici, loro procedimento di preparazione e loro impiego in medicina umana e veterinaria ed in cosmetica.
HUP0002979A2 (hu) Terápiásan több célú, ösztrogén agonista és antagonista vegyületek alkalmazása
ATE485783T1 (de) Vorrichtung zur interstitiellen laserbehandlungvon kleinen brustkrebsgeschwülsten und damit verbundene therapie
PL323363A1 (en) Biaromatic propynyl or dienyl compounds
MXPA02009744A (es) Uso de fulvestrant en el tratamiento de cancer resistente de mama.
IT1208048B (it) Composti naftil aromatici, loro procedimento di preparazione e loro impiego in medicina umana e veterinaria e in cosmetica.
DE69912477D1 (de) Endokrintherapie für brustkrebs: kombinierte behandlung mit tamoxifen und alkyl-pcdfs
RS37804A (en) Use of n,n-diethyl-2-/-4-(phenylmethyl)- phenoxy/ethanamine monohydrochloride (dppe)in cancer therapy
Aschwanden et al. Hell on heels.
Lee et al. Polyamines Regulate Protein Phosphorylation in MCF-7 Human Breast Cancer Cells
GB0120926D0 (en) Proteins,genes and their use for diagnosis and treatment of breast cancer
Carey et al. Alcohol and estrogen: a risky cocktail?
AU2003253050A1 (en) Diagnosis and therapy of breast tumours resistant to antiestrogen treatment
KR20030077743A (ko) In½
TW527918U (en) Medical chest strap dedicated for breast cancer patient
GB0110908D0 (en) Proreins, genes and their use for diagnosis and treatment of breast cancer
Nolan The role of HRT and SERMs: Evidence-based medicine
Taubes Zinc and the common cold.
Tieman Carolyn Lewis dies at 65.
Piotrowski Immigrant therapy.